Tiantan Biological's Q3 net profit drops 42% amid falling sales prices

Beijing Tiantan Biological Products Co. Ltd. reported a significant decrease in key financial metrics for the third quarter and the first nine months of 2025. For the third quarter, net profit attributable to shareholders plunged by 42.84% to 186,124,194.35 yuan, with total profit falling 42.14% to 309,027,126.09 yuan. Basic and diluted earnings per share also saw a 42.84% decline to 0.09 yuan.

This decline was primarily attributed to a decrease in sales prices and increased credit impairment losses impacting the company's profitability. Despite these challenges, the company’s operating income for the quarter rose by 9.96% to 1,354,678,903.64 yuan.

For the first nine months of 2025, net profit attributable to shareholders decreased by 22.16% to 818,686,340.45 yuan. Operating cash flow for the nine-month period dramatically fell by 91.00% to 116,895,028.07 yuan, largely due to changes in credit policies reducing cash received from sales and increased tax payments.